Travere Therapeutics reports Q1 EPS 5c, consensus (5c)

Reports Q1 revenue $127.2M, consensus $136.8M. “This has been a transformative start to the year for Travere, highlighted by the landmark approval of FILSPARI in FSGS, record demand that reinforces FILSPARI’s foundational position in IgAN, and the advancement of pegtibatinase with the first new patient dosed in the restarted Phase 3 HARMONY study,” said Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics (TVTX). “With FILSPARI now positioned to help more than 100,000 patients across IgAN and FSGS, we see a substantial and durable growth opportunity ahead, supporting a compelling long-term trajectory for the Company.”